Alteogen Secures Domestic Approval for Eylea Biosimilar ‘Eyenefy Injection’
Securing Domestic Approval Following Europe
Subsidiary Also Advancing Development of 'ALTS-OP01'
On May 15, Alteogen announced that it has received domestic product approval from the Ministry of Food and Drug Safety for 'Eyenefy® Injection (project name ALT-L9, an aflibercept biosimilar)'.
ALT-L9, which was approved in Europe last year under the product name 'Eyluxvi®', has now also secured approval in Korea. Based on this product approval, Alteogen plans to launch the product in the domestic market.
The approval for Eyenefy Injection is based on the results of global phase 3 clinical trials conducted in 12 countries, including Europe, Korea, and Japan, by its subsidiary Alteogen Biologics. In these trials, ALT-L9 demonstrated therapeutic equivalence and safety compared to the original drug, Eylea.
Alteogen Biologics is currently developing 'ALTS-OP01', a candidate therapeutic for macular degeneration, leveraging its global clinical and regulatory capabilities. ALTS-OP01 is a new drug candidate designed to improve efficacy and extend dosing intervals compared to existing treatments. Alteogen is also strengthening its pipeline for subsequent ophthalmic therapies, including filing an international patent (PCT) for high-dose formulation technology.
Tae-yeon Jeon, CEO of Alteogen, stated, "Eyenefy Injection was developed based on Alteogen's accumulated expertise in protein drug development and formulation research, and our subsidiary Alteogen Biologics led the global clinical development and regulatory procedures. Securing domestic product approval following European approval demonstrates Alteogen's capabilities in global clinical development and regulatory compliance."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
He added, "Building on our accumulated clinical development capabilities and regulatory experience, we will continue to grow as a global biopharmaceutical company with both platform technology and development expertise."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.